Diseembar 2021: Daawaynta CAR T-Cell ayaa hadda loo oggolaaday noocyo ka mid ah leukemia, lymphoma, iyo myeloma badan. Cilmi baadhayaashu hadda waxay soo saareen daawaynta u dhiganta GD2 CAR T-cell ee daawaynta neuroblastoma, tusaale ahaan, burooyinka maskaxda carruurnimada. Kansarka sambabada, kansarka caloosha, kansarka beerka, kansarka naasaha, iyo kansarka kale ee dadka waaweyn ayaa leh dhacdooyinka ugu sarreeya. Marka laga hadlayo kansarka carruurta, dad badan ayaa si dareen leh u aaminsan inuu la mid yahay kansarka dadka waaweyn.
However, whether it is the cause of cancer or the type of cancer, there is a significant difference between childhood cancer and adult cancer. The most frequent childhood tumour is neuroblastoma, which is more common than lung cancer, gastric cancer, and other cancers. Neuroblastoma can account for half of all cancers in children under the age of five, greatly exceeding the proportion of various malignancies in adult cancers.
Si kastaba ha noqotee, heerka badbaadada 5-sano ee bukaanada neuroblastoma wali maaha mid aad u weyn, oo ku dhawaad 40% ilaa 50% bukaanada wali ma awoodaan inay helaan daawo waqti dheer ah. Sidoo kale, haddii buradu soo noqoto, ilmuhu weli khatar buu ku jiraa, si la mid ah waxa dhaca marka kansarka qaangaarka ahi soo laabto.
Ma jirtaa daaweyn cusub oo la heli karo?
Daaweynta unugyada CAR-T has opened up a whole new universe in the field of advanced relapse and refractory B-cell cancers in recent years, and it has also allowed people to witness how effective it can be.
As a result, researchers have created a GD2-CAR-T cell therapy for the treatment of neuroblastoma for the matching target of neuroblastoma. The findings of the clinical study were published in the most recent issue of “Science Translational Medicine.”
Tijaabadaan waxaa ku jiray wadar ahaan 12 carruur ah oo soo noqnoqday/dib-u-soocday neuroblastoma. Guud ahaan, daawadu si fiican ayaa loo dulqaatay, wax saamayn ah oo ka baxsan bartilmaameedka lama arag. In kasta oo xaqiiqda ah in aanay gaadhin jawaab celin caafimaad oo ujeedo leh, cilmi-baarayaashu waxay ogaadeen faa'iido daweyn oo dhab ah oo shakhsiyaadka qaarkood ah.
Bukaan-socodka 25/010 waa gabar 8-jir ah oo leh metastases neuroblastoma oo ballaaran, oo ay ku jiraan lafo-baxyo muhiim ah (soo noqnoqda ka dib daaweynta safka afraad). Xaaladda guud ayaa si aad ah u soo hagaagtay 28 maalmood ka dib Daaweynta unugyada CAR-T, iyo unugyada burooyinka ayaa sidoo kale muujiyay buro necrosis oo baahsan.
Bukaanka 25/013 waa gabadh 10 jir ah oo shan daawayn u samaysay neuroblastomas maxalli ah oo soo noqnoqda. Waxaa jiray qanjidhada buro ee luqunta ka hor daawaynta ka hor, laakiin majirin wax ka fogaansho. MRI waxay muujisay in buradu ay yaraatay daawaynta ka dib. Ka dib markii la soo gooyay buro, waxaa la ogaaday in buradu ay leedahay necrosis weyn.
Bukaanka 25/018 waa ilmo 10 jir ah oo qaba neuroblastoma oo soo noqnoqda oo ku faafay jidhkiisa oo dhan. Waxa uu yeeshay saddex kalfadhi ka hor iyo ka dib, dhibaatadiisana waa la fududeeyay natiijada daaweynta.
Si kastaba ha noqotee, iyada oo daraasaddan ay muujisay in daaweyntu ay waxtar leedahay, ka dib markii ay la kulantay heerka ugu sarreeya ee daaweynta unugyada CAR-T, ballaarinta muddada dheer ee unugyada CAR-T ma muuqato, taasoo ka dhigaysa saameynta daaweynta mid aan waxtar lahayn. Waxay ugu dambeyntii keentay soo noqoshada buro, si kastaba ha ahaatee, ka hor, daawayntani waxay caawisay 013 iyo 018 inay noolaadaan qiyaastii 5 bilood ka dheer.
Although this new CAR-T cell therapy cannot match the efficacy and durability of CD19-CAR-T cell therapy in haematological cancers, it demonstrates that CAR-T cell therapy can still be employed in the entity once a suitable target is identified. In the treatment of tumours, it has potent anti-tumor effects. To improve its therapeutic efficacy in solid malignancies, researchers will combine CAR-T activation with immune checkpoint drugs (PD-1 inhibitors).
Badbaadada buradan adag daawaynta unugga CAR-T waa la hubaa hadda. Bukaanku wuxuu helay CRS natiijadii daawadii, in kasta oo aysan dhicin falcelin neurotoxic ah. Kooxaha caafimaadka ee qaata daawaynta unugga CAR-T waxa laga yaabaa inay dhawaan u jawaabaan CRS arrin ahaan. Daaweynta unugyada CAR-T wali waxay haysaa waddo dheer oo loo maro marka la eego ka gudubka burooyinka adag, laakiin waxay halkaas gaari doontaa maalin.
